Prognostic value of 18F-FDG PET/MRI in patients with advanced oropharyngeal and hypopharyngeal squamous cell carcinoma.
Aged
Chemoradiotherapy
Female
Fluorodeoxyglucose F18
/ chemistry
Follow-Up Studies
Glycolysis
Head and Neck Neoplasms
/ diagnostic imaging
Humans
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Positron-Emission Tomography
/ methods
Prognosis
Radiopharmaceuticals
/ chemistry
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ diagnostic imaging
Survival Analysis
Tumor Burden
FDG
Oropharyngeal and hypopharyngeal cancer
Overall survival
PET/MRI
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
04
11
2020
accepted:
12
01
2021
pubmed:
13
2
2021
medline:
26
10
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
The aim of this study was to evaluate the prognostic value of combined positron emission tomography (PET)/magnetic resonance imaging (MRI) parameters provided by simultaneous 18F-fluorodeoxyglucose (FDG) PET/MRI in patients with locally advanced oropharyngeal and hypopharyngeal squamous cell carcinomas (OHSCC). Forty-five patients with locally advanced OHSCC who underwent simultaneous FDG PET/MRI before (chemo)radiotherapy were retrospectively enrolled. Peak standardized uptake value (SULpeak), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of the primary lesion were obtained on PET data. On MRI scans, primary tumor size, diffusion and perfusion parameters were assessed using pre-contrast and high-resolution post-contrast images. Ratios between metabolic/metabolo-volumetric parameters and ADC were calculated. Comparisons between groups were performed by Student's t test. Survival analysis was performed by univariate Cox proportional hazard regression analysis. Overall survival curves were obtained by the Kaplan-Meier method and compared with the log-rank test. Survivors were censored at the time of the last clinical control. p < 0.05 was considered statistically significant RESULTS: During follow-up (mean 31.4 ± 21 months), there were 15 deaths. Univariate analysis shows that SULpeak and SULpeak/ADCmean were significant predictors of overall survival (OS). At multivariate analysis, only SULpeak remained a significant predictor of OS. Kaplan-Meier survival analyses showed that patients with higher SULpeak had poorer outcome compared to those with lower values (HR: 3.7, p = 0.007). Pre-therapy SULpeak of the primary site was predictive of overall survival in patients with oropharyngeal or hypopharyngeal cancer treated with (chemo)radiotherapy.
Identifiants
pubmed: 33575927
doi: 10.1007/s12149-021-01590-y
pii: 10.1007/s12149-021-01590-y
pmc: PMC7981313
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
479-484Références
Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1607-19
pubmed: 21567252
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1297-1308
pubmed: 29502310
Eur J Radiol. 2017 Mar;88:47-55
pubmed: 28189208
Eur Radiol. 2014 Jan;24(1):223-31
pubmed: 24013848
EJNMMI Res. 2018 Jan 10;8(1):2
pubmed: 29322269
Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1066-75
pubmed: 24577950
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2122-2138
pubmed: 29948105
Eur J Radiol. 2014 Feb;83(2):289-96
pubmed: 24331845
Eur J Radiol. 2015 Jul;84(7):1269-76
pubmed: 25958189
Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):639-48
pubmed: 24292211
Magn Reson Imaging Clin N Am. 2018 Feb;26(1):121-133
pubmed: 29128000
J Nucl Med. 2017 Dec;58(12):1919-1924
pubmed: 28572489
Eur J Radiol. 2019 Apr;113:39-50
pubmed: 30927958
Nagoya J Med Sci. 2017 Feb;79(1):27-36
pubmed: 28303058
Oral Oncol. 2019 Jan;88:109-114
pubmed: 30616780
Lancet Oncol. 2019 Jun;20(6):e313-e326
pubmed: 31162105
Cancer Med. 2014 Oct;3(5):1368-76
pubmed: 25045041
Eur Radiol. 2016 Nov;26(11):4162-4172
pubmed: 26911889
Med Oncol. 2018 Jun 19;35(7):112
pubmed: 29922943
Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):996-1008
pubmed: 21327634
Contrast Media Mol Imaging. 2017 Oct 19;2017:5369625
pubmed: 29114177
Eur J Nucl Med Mol Imaging. 2014 Dec;41(12):2212-21
pubmed: 25091219
Eur Radiol. 2014 Aug;24(8):1998-2004
pubmed: 24838795
J Cancer Res Clin Oncol. 2011 Jul;137(7):1085-93
pubmed: 21229262
J Nucl Med. 2014 Apr;55(4):551-8
pubmed: 24491410
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):92-102
pubmed: 26243264
AJNR Am J Neuroradiol. 2014 Oct;35(10):1970-5
pubmed: 24924545
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):94-104
pubmed: 31606831
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):462-75
pubmed: 24108458
Head Neck. 2015 Oct;37(10):1524-31
pubmed: 24890445
Oncotarget. 2017 Mar 4;8(37):62606-62621
pubmed: 28977973